Intellia Therapeutics Receives Priority Medicines Designation From The European Medicines Agency For NTLA-2002, An Investigational In Vivo CRISPR Genome Editing Treatment For Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics has received Priority Medicines designation from the European Medicines Agency for NTLA-2002, an investigational in vivo CRISPR genome editing treatment for Hereditary Angioedema.
October 13, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia Therapeutics' NTLA-2002 has been granted Priority Medicines designation by the European Medicines Agency, potentially accelerating its path to market.
The Priority Medicines designation is a significant regulatory milestone that could accelerate the development and review of NTLA-2002. This could potentially lead to faster market access, benefiting Intellia Therapeutics in terms of competitive advantage and potential revenue generation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100